We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $529M
1-Year Est. Return 337.4%
This Fund
S&P 500
This Quarter Est. Return
+27.32%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.24%
AUM
$529M
AUM Growth
+$94M
Cap. Flow
-$41.6M
Cap. Flow %
-7.87%
Top 10 Hldgs %
51.64%
Holding
54
New
12
Increased
7
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$23.1M
2
VERA icon
Vera Therapeutics
VERA
+$15M
3
SGMT icon
Sagimet Biosciences
SGMT
+$13.8M
4
DFTX
Definium Therapeutics
DFTX
+$10.5M
5
IMMX icon
Immix Biopharma
IMMX
+$8.61M

Top Sells

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$31.5M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$16.2M
3
KALV
KalVista Pharmaceuticals
KALV
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$13.6M
5
JBIO
Jade Biosciences
JBIO
+$13.6M

Sector Composition

Rank Sector Weight
1 Healthcare 78.18%
2 Miscellaneous 19.78%
3 Financials 2.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
51
Pharvaris
PHVS
$2.67B
– –
-82,800
Closed -$2.34M
TENX icon
52
Tenax Therapeutics
TENX
$68.5M
– –
-327,307
Closed -$5.23M
UNCY icon
53
Unicycive Therapeutics
UNCY
$131M
– –
-796,558
Closed -$5.24M
ZBIO
54
Zenas BioPharma
ZBIO
$2.08B
– –
-524,066
Closed -$10.2M
1 2
3

Similar funds

KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
FFIC
First Fiduciary Investment Counsel Cleveland, Ohio $529M AUM 15.02% 1-Year Est. Return
TA
Teramo Advisors Naples, Florida $529M AUM 20.59% 1-Year Est. Return
JDLA
J. Derek Lewis & Associates Newport Beach, California $529M AUM
CCG
Clearlake Capital Group Santa Monica, California $529M AUM 50.26% 1-Year Est. Return
DAS
DMKC Advisory Services Des Moines, Iowa $530M AUM 22.27% 1-Year Est. Return
VAMG
Voisard Asset Management Group Grand Rapids, Michigan $529M AUM 21.43% 1-Year Est. Return
CWM
Compass Wealth Management Guilford, Connecticut $528M AUM 40.26% 1-Year Est. Return

Great Point Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Great Point Partners held 54 positions worth $529M, up 22% from $435M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners withdrew a net $41.6M in Q2 2026, closing 12 positions and reducing 10 holdings. Its most notable exit was Apogee Therapeutics, an estimated $31.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Great Point Partners opened a new position in Abivax worth $27.2M.

  • Great Point Partners's largest Q2 2026 buy was Abivax: 204,314 shares worth $27.2M.
  • Great Point Partners added most to Vera Therapeutics in Q2 2026, an estimated $15M increase.
  • Great Point Partners's biggest Q2 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $16.2M.
  • Great Point Partners fully exited Apogee Therapeutics in Q2 2026, selling an estimated $31.5M.
  • Great Point Partners's ten largest holdings make up 52% of its $529M portfolio in Q2 2026.
  • Great Point Partners opened 12 new positions and closed 12 in Q2 2026.
  • Great Point Partners's portfolio value rose 22% quarter-over-quarter to $529M.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.